Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

Mechanisms of acquired resistance

These three clinical trials (LOXO-TRK-14001, SCOUT and NAVIGATE) also investigated the mechanisms of acquired resistance to larotrectinib (i.e. disease progression during treatment after a documented objective response or stable disease for ≥6 months), which was observed in 10 patients and further characterised in 9 patients [1]. These included solvent-front substitutions in 7 patients, gatekeeper substitutions in 2 patients, and xDFG substitutions in 2 patients. Three patients had more than one acquired resistance mutation. Among these 10 patients, 80% continued treatment with larotrectinib beyond progression because of ongoing clinical benefit.

Reference

  1. Loxo Oncology. VITRAKVI® (larotrectinib) [prescribing information]. In. Stamford, CT: Loxo Oncology, Inc. 2018.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings